{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"VYNE Therapeutics Inc."},"Symbol":{"label":"Symbol","value":"VYNE"},"Address":{"label":"Address","value":"520 U.S. HIGHWAY 22,SUITE 204 SUITE 301, BRIDGEWATER, New Jersey, 08807, United States"},"Phone":{"label":"Phone","value":"+1 800 775-7936"},"Industry":{"label":"Industry","value":"Biotechnology: Pharmaceutical Preparations"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its most advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds."},"CompanyUrl":{"label":"Company Url","value":"https://www.vynetherapeutics.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"David Domzalski","title":"President, Chief Executive Officer & Director"},{"name":"Iain A. Stuart","title":"Chief Scientific Officer"},{"name":"Subhashis Banerjee","title":"Senior Vice President-Clinical Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}